Base documentaire
-
Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.
JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 87, n° 7, 1995, pages 524-530, 33 réf., ISSN 0027-8874, USA
TRAVIS (L.B.), CURTIS (R.E.), GLIMELIUS (B.), HOLOWATY (E.J.), VAN LEEUWEN (F.E.), LYNCH (C.F.), HAGENBEEK (A.), STOVALL (M.), BANKS (P.M.), ADAMI (J.), GOSPODAROWICZ (M.K.), WACHOLDER (S.), INSKIP (P.D.), TUCKER (M.A.), BOICE (Jdjr)
National cancer inst. Epidemiology biostatistics program. Div cancer etiology. Bethesda MD. USA
Background
Cyclophosphamide is an established bladder carcinogen, but few studies have examined the relationship between dose and effect.
The largest analysis to date included only seven cases of bladder cancer.
No investigation has estimated the risk of kidney cancer.
Purpose
The purpose of this study was to quantify the risk of bladder and kidney cancer following cyclophosphamide therapy.
Methods
Within a cohort of 6171 two-year survivors of non-Hodgkin's lymphoma (NHL), 48 patients with secondary cancer of the urinary tract were identified and matched to 136 control subjects with NHL who did not develop a second malignancy.
Detailed information on chemotherapeutic drugs and cumulative dose received was collected for all subjects.
Radiation dose to the target organ was estimated from individual radiotherapy records.
Evaluations of the risk of second cancer as a result of treatment with cyclophosphamide alone ; radiation alone, or both therapies were made relative to those patients who were exposed to neither treatment modality.
Results
A significant 4.5-fold risk of bladder cancer (95% confidence interval [CI]=1.5-13.6) followed therapy with cyclophosphamide, and risk was dependent upon cumulative dose.
Among patients who received a total amount of cyclophosphamide of less than 20 g, a nonsignificant 2.4-fold risk of bladder cancer was apparent.
Mots-clés BDSP : Médicament anticancéreux, Thérapeutique médicamenteuse, Thérapeutique, Cancer, Vessie, Carcinogène, Facteur risque, Epidémiologie, Etats Unis, Amérique, Canada, Suède, Europe, Complication, Homme, Appareil urinaire [pathologie], Rein [pathologie]
Mots-clés Pascal : Lymphome non hodgkinien, Cyclophosphamide, Agent alkylant, Anticancéreux, Chimiothérapie, Traitement, Tumeur maligne, Vessie urinaire, Rein, Second cancer, Carcinogène, Toxicité, Facteur risque, Epidémiologie, Etats Unis, Amérique du Nord, Amérique, Canada, Suède, Europe, Complication, Homme, Hémopathie maligne, Lymphoprolifératif syndrome, Vessie pathologie, Appareil urinaire pathologie, Voie urinaire pathologie, Rein pathologie, Etude cas témoin
Mots-clés Pascal anglais : Non Hodgkin lymphoma, Alkylating agent, Antineoplastic agent, Chemotherapy, Treatment, Malignant tumor, Urinary bladder, Kidney, Second cancer, Carcinogen, Toxicity, Risk factor, Epidemiology, United States, North America, America, Canada, Sweden, Europe, Complication, Human, Malignant hemopathy, Lymphoproliferative syndrome, Bladder disease, Urinary system disease, Urinary tract disease, Renal disease, Case control study
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et TechniqueCote : 95-0352549
Code Inist : 002B02U10. Création : 01/03/1996.
Banque de données en santé publique - http://www.bdsp.ehesp.fr/